Clinical Trial Update: Phase 3 Study of Cysteamine Bitartrate Delayed-release (RP103) Compared to Cystagon® in Patients With Cystinosis [Phase 3]

View source ↗

Summary

Phase 3 trial comparing cysteamine bitartrate delayed-release (RP103) to Cystagon in patients with cystinosis completed; results were posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystinosis

Drugs mentioned

• Cystagon (cysteamine bitartrate)
• Cysteamine bitartrate delayed-release (RP103) (cysteamine bitartrate delayed-release)

Snippet

Sponsor: Amgen | Conditions: Cystinosis | Phase 3 | Status: COMPLETED | Results posted: 2014-11-19